Yumi Kubo

952 total citations
13 papers, 682 citations indexed

About

Yumi Kubo is a scholar working on Nephrology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yumi Kubo has authored 13 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Nephrology, 3 papers in Pediatrics, Perinatology and Child Health and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yumi Kubo's work include Parathyroid Disorders and Treatments (9 papers), Dialysis and Renal Disease Management (5 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Yumi Kubo is often cited by papers focused on Parathyroid Disorders and Treatments (9 papers), Dialysis and Renal Disease Management (5 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Yumi Kubo collaborates with scholars based in United States, United Kingdom and Canada. Yumi Kubo's co-authors include Patrick S. Parfrey, Glenn M. Chertow, Jürgen Floege, Geoffrey A. Block, Bastian Dehmel, William G. Goodman, Kenneth W. Mahaffey, David C. Wheeler, Tilman B. Drüeke and Charles A. Herzog and has published in prestigious journals such as Circulation, Neurology and American Journal of Kidney Diseases.

In The Last Decade

Yumi Kubo

13 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yumi Kubo United States 10 552 212 186 131 113 13 682
Martha S. Persky United States 11 638 1.2× 345 1.6× 162 0.9× 90 0.7× 121 1.1× 12 792
Jürgen Floege Germany 5 441 0.8× 174 0.8× 132 0.7× 107 0.8× 136 1.2× 8 559
Kurt Sowers United States 6 472 0.9× 122 0.6× 129 0.7× 93 0.7× 86 0.8× 6 681
Jin Tian United States 8 292 0.5× 66 0.3× 259 1.4× 54 0.4× 72 0.6× 8 537
Masaki Ohya Japan 14 324 0.6× 81 0.4× 101 0.5× 92 0.7× 79 0.7× 38 564
Dorota Szumilak France 7 246 0.4× 92 0.4× 44 0.2× 117 0.9× 78 0.7× 9 490
Celina Franco Sweden 12 396 0.7× 52 0.2× 130 0.7× 164 1.3× 33 0.3× 12 688
Johannes Törnig Germany 14 537 1.0× 86 0.4× 80 0.4× 122 0.9× 160 1.4× 17 946
Edward Chong United States 7 323 0.6× 139 0.7× 48 0.3× 56 0.4× 97 0.9× 8 516
Alfredo Vallo Spain 19 371 0.7× 207 1.0× 137 0.7× 93 0.7× 373 3.3× 61 1.2k

Countries citing papers authored by Yumi Kubo

Since Specialization
Citations

This map shows the geographic impact of Yumi Kubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yumi Kubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yumi Kubo more than expected).

Fields of papers citing papers by Yumi Kubo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yumi Kubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yumi Kubo. The network helps show where Yumi Kubo may publish in the future.

Co-authorship network of co-authors of Yumi Kubo

This figure shows the co-authorship network connecting the top 25 collaborators of Yumi Kubo. A scholar is included among the top collaborators of Yumi Kubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yumi Kubo. Yumi Kubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Depré, Christophe, Amaal J. Starling, Michael J. Koren, et al.. (2018). A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable Angina (S32.004). Neurology. 90(15_supplement). 3 indexed citations
3.
4.
Briggs, Andrew, Patrick S. Parfrey, Nasreen Khan, et al.. (2016). Analyzing Health-Related Quality of Life in the EVOLVE Trial. Medical Decision Making. 36(8). 965–972. 20 indexed citations
5.
Parfrey, Patrick S., Tilman B. Drüeke, Geoffrey A. Block, et al.. (2015). The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Queensland's institutional digital repository (The University of Queensland). 5 indexed citations
6.
Moe, Sharon M., Glenn M. Chertow, Patrick S. Parfrey, et al.. (2015). Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation. 132(1). 27–39. 228 indexed citations
7.
Gillespie, Iain, Jürgen Floege, Tilman B. Drüeke, et al.. (2015). Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all‐cause mortality. Pharmacoepidemiology and Drug Safety. 24(7). 738–747. 10 indexed citations
8.
Floege, Jürgen, et al.. (2015). The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology. 10(5). 800–807. 96 indexed citations
9.
Parfrey, Patrick S., Tilman B. Drüeke, Geoffrey A. Block, et al.. (2015). The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology. 10(5). 791–799. 65 indexed citations
10.
Kubo, Yumi, Lulu Ren Sterling, Patrick S. Parfrey, et al.. (2015). Assessing the treatment effect in a randomized controlled trial with extensive non‐adherence: the EVOLVE trial. Pharmaceutical Statistics. 14(3). 242–251. 15 indexed citations
11.
Wheeler, David C., Gérard M. London, Patrick S. Parfrey, et al.. (2014). Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Journal of the American Heart Association. 3(6). e001363–e001363. 97 indexed citations
12.
13.
Locatelli, Francesco, H. E. Abboud, Ángel L.M. de Francisco, et al.. (2008). A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis. American Journal of Kidney Diseases. 53(2). 197–207. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martha S. Persky Breakdown of academic impact, for papers by Jürgen Floege Breakdown of academic impact, for papers by Kurt Sowers Breakdown of academic impact, for papers by Jin Tian Breakdown of academic impact, for papers by Masaki Ohya Breakdown of academic impact, for papers by Dorota Szumilak Breakdown of academic impact, for papers by Celina Franco Breakdown of academic impact, for papers by Johannes Törnig Breakdown of academic impact, for papers by Edward Chong Breakdown of academic impact, for papers by Alfredo Vallo
Rankless by CCL
2026